SIX Swiss Exchange reviews publicly listed companies included in 'Highlights of 2025: Year in Review' (see PDF edition, pages 56 to 59). This year it recognizes the notable success of BioVersys, which has rapidly grown from an ETH spin-off to become the first SIX biotech IPO since 2018.

For the 15th consecutive year, Switzerland tops the Global Innovation Index (GII), leading globally in knowledge and technology outputs and creative industries, even amid global R&D and venture capital headwinds. This sustained performance reflects a powerful mix of exceptional talent, deep collaboration, and long-term commitment to innovation.

Switzerland's strength as a global biotech hub is often described in terms of innovation, productivity, and quality. At the heart of all three lies a decisive factor: talent. From early scientific discovery to large-scale manufacturing and global commercial leadership, Switzerland offers a talent ecosystem that supports the entire biotech value chain.

Switzerland is the chosen location of a large number of world-class biomanufacturing facilities. In addition to its strong focus on therapeutics and drug products, Switzerland's biomanufacturing sector extends beyond the pharmaceutical industry. Strong talent, innovation, collaboration, and long-term strategy are some of the factors that underpin Switzerland's global impact.

In recent years, against a backdrop of geopolitical uncertainty and market volatility, Switzerland's biotech sector has delivered continued growth, powered by innovation, talent, and tenacity. Annual growth rates of around 5% have been supported by sustained levels of R&D investments, record funding, and accelerated startup creation by venture builders.